2025 CPT code 0379U
(Active) Effective Date: N/A Revision Date: N/A Deletion Date: N/A Pathology and Laboratory - Genomic Sequencing Procedures (GSP) Proprietary Laboratory Analyses Feed
Targeted genomic sequence analysis panel for solid organ neoplasms, analyzing DNA (523 genes) and RNA (55 genes) via next-generation sequencing (NGS) to identify sequence variants, gene copy number amplifications, rearrangements, microsatellite instability, and tumor mutational burden.
Modifiers may apply depending on the circumstances of service. Consult modifier guidelines.
Medical necessity for 0379U is determined by the presence of a solid tumor for which genomic profiling is clinically indicated for treatment selection, prognosis, or diagnosis. Factors considered include tumor type, stage, prior treatments, and the patient’s overall health. Payer-specific guidelines for coverage should be consulted.
A clinical laboratory scientist performs the test, analyzes the results, and prepares a report for the ordering physician. The physician is responsible for interpreting the results within the context of the patient's clinical presentation and for making treatment decisions.
In simple words: This lab test uses advanced technology to analyze a tumor sample's genes. It checks for changes in the genes that might help doctors decide on the best diagnosis, treatment, and prediction of the cancer's future course.The test is done by Quest Diagnostics.
CPT code 0379U represents a proprietary laboratory analysis (PLA) encompassing a targeted genomic sequence analysis panel designed for solid organ neoplasms.The test utilizes next-generation sequencing (NGS) technology to evaluate both DNA (523 genes) and RNA (55 genes) within a tumor specimen.Analysis includes the identification of sequence variants (single nucleotide variants [SNVs], insertions/deletions [InDels]), gene copy number amplifications, gene rearrangements, microsatellite instability (MSI), and tumor mutational burden (TMB). The results contribute to diagnosis, prognosis, and treatment selection for patients with solid tumors.This test is specifically the Solid Tumor Expanded Panel from Quest Diagnostics.
Example 1: A 65-year-old male patient presents with a newly diagnosed lung adenocarcinoma.The ordering physician requests 0379U to assess the tumor’s genomic profile for potential treatment targets, such as driver mutations, and to inform prognosis., A 48-year-old female patient with metastatic breast cancer undergoes a biopsy. The oncologist orders 0379U to identify potential therapeutic targets for targeted therapy and to evaluate for biomarkers predicting response to specific treatments., A 72-year-old patient with colorectal cancer undergoes surgical resection.Pathology sends the sample for 0379U testing to look for biomarkers associated with recurrence risk and to guide adjuvant therapy decisions.
* Patient demographics and medical record number.* Ordering physician information.* Date of service.* Specimen type (e.g., tumor tissue, blood).* Complete pathology report with tissue diagnosis.* Detailed clinical history and reason for ordering the test.* Results of 0379U analysis from Quest Diagnostics.
** This code is specific to the Solid Tumor Expanded Panel from Quest Diagnostics.Other similar tests may have different PLA codes.Always verify the correct code with the laboratory performing the test and refer to payer-specific guidelines for coverage and reimbursement.Accurate coding requires detailed documentation and adherence to NCCI edits.
- Revenue Code: Z2 (Undefined Codes)
- RVU: Not specified in available sources.RVUs would be determined by the payer.
- Global Days : Not applicable; this is a laboratory test, not a surgical procedure.
- Payment Status: Active
- Modifier TC rule: Not applicable; this is a complete lab test.
- Fee Schedule : Fee schedules vary by payer and are subject to change.Refer to specific payer contracts or fee schedules.
- Specialties:Oncology, Pathology, Medical Oncology
- Place of Service:Laboratory, Hospital, Physician's Office